View in browser

The UC San Diego, School of Medicine solidified its status as a national leader in NIH funding, as reported by the 2023 Blue Ridge Institute for Medical Research rankings. In total, the School of Medicine received more than $460 million in NIH grants in 2023, positioning it 5th among public institutions and 13th overall.  

This leadership position provides oversight of the Shared Resources at Moores and is open to current UC San Diego faculty who possess (1) extensive cancer relevant research experience, (2) a proven extramural funding track record, and (3) demonstrated management experience. Applications are due by 5:00 p.m. on Monday, April 22, 2024.

For questions, contact Mark Garcia at markgarcia@health.ucsd.edu.

Great science is not enough to secure NIH grants—grantspersonship skills also must be mastered. In addition to the grant development and submission support available to Moores Members from the Moores Grant Development Team and Pre-Award Research Administration, UC San Diego currently is piloting a 1-year institutional membership that gives faculty and staff free access to a suite of NIH grant development resources, created by the Bouvier Grant Group . These online, self-paced resources are a US$6,000 value and address F, K, P, R, and U series grants; typical submission mistakes and best practices; proposal checklists; and time management strategies, among other topics. Moreover, an “Ask the Grantwriting Expert'' virtual office hour component enables the ability to ask questions about submissions in real time.

Dr. Ludmil Alexandrov, Member of the Moores Structural and Functional Genomics Research Program, was among the 162 new AIMBE Fellows who were recognized at the AIMBE Annual Event on March 25, 2024. Dr. Alexandrov develops next-generation computational tools and combines them with novel experimental techniques to elucidate how human cancers develop and grow, which has led to the development of improved strategies to prevent and treat cancer. 

Dr. Shweta Joshi was awarded the 2023 CurePrize for translating foundational preclinical studies, which resulted from collaboration between Dr. Joshi and Dr. Andy Lowy, which will determine whether combining Fostamatinib, an FDA-approved drug that blocks Syk function, with chemotherapy prior to surgery improves patient outcomes. Moreover, Dr. Joshi was awarded the 2023 CureBound Discovery 2023 with Dr. Dan Kaufman. Their project investigates whether targeting immunosuppressive myeloid cells can enhance responses to anti-GD2 immunotherapy and explores the combination of “off-the-shelf” human iPSC-derived natural killer cells to improve survival of children with neuroblastoma.

April 17, 2024 | 12:00 p.m. to 1:00p.m.

Comer Commons 

April 17, 2024 | 12:00 p.m.

Biomedical Sciences Building Garren Auditorium

May 1, 2024 | 12:00 p.m. to 1:00p.m.

Comer Commons

May 10, 2024 | 12:00 p.m. to 1:00p.m.

Comer Commons

May 17, 2024 | 8:00 a.m. to 7:00 p.m.

Sanford Burnham Prebys Fishman Auditorium

An NCI Program Director will present on how diversity-focused awards, supplements, and fellowships can support the recruitment, retention, and advancement of diverse investigators. A panel of PI-scholar dyads will share their success stories.

April 25, 2024 | 8:30 a.m. to 10:30 a.m and 1:00 p.m. to 3:00 p.m.

The UC San Diego Health Sciences Office of Faculty Affairs will offer training in effective mentoring for junior faculty, presented by Moores Member Dr. Judith Varner (UC San Diego) and Dr. Dennis Durbin (Ohio State University and Nationwide Children’s Hospital).

Two in-person sessions will be available–please register for only one:

Moores OTS is accepting requests for the Speed Networking Initiative to advance endeavors in translational research. This initiative offers the opportunity to connect with potential collaborators who could lend expertise to translational research. Moores OTS fosters collaboration among Moores investigators and facilitates connections that drive impactful translational research. Complete the form below if you seek collaborators to join your translational project.

Pre-Award Services–these services are provided for investigators and/or research in the Moores space:

Grant Development Services–these services are provided for all Moores Members, based on priority:

April 18, 2024 | 3:00 p.m. to 4:00 p.m.

The UC San Diego, Office of Research and Innovation invites you to join this webinar presented by the Conafay Group to (1) understand the unique priorities and operational needs of the DoD and (2) gain a strategy for aligning NIH research proposals accordingly to address essential defense health needs. Please contact vcri-initiatives@ucsd.edu with any questions.

This award was established to accelerate innovation in cancer research for women, by women. It funds innovative research that targets outcomes for women's cancers and supports the next generation of women scientists who represent the population they serve. By targeting prevention, detection, diagnostic, and treatment innovations for women’s cancers and advancing outcomes for cancer health disparities, Victoria’s Secret will improve and save the lives of millions of women worldwide.

Application Deadline: May 15, 2024

This grant is the AACR’s flagship funding initiative to stimulate highly innovative research from young investigators through supporting creative, paradigm shifting cancer research that may not be funded through conventional channels. Proposed projects must catalyze tangible scientific discoveries and help talented young investigators gain scientific independence. Although proposed research may be basic, translational, or clinical in nature, in any area of cancer research, the 2024 TNBCF-AACR NextGen Grant will be awarded to projects that address only triple negative breast cancer.

Letter of Intent Deadline: May 16, 2024

Journal of Clinical Oncology

Jason Sicklick, MD (Structural and Functional Genomics)

Science Translational Medicine

Aaron Miller, MD, PhD (Solid Tumor Therapeutics), Scott Lippman, MD (Cancer Control Program), Alessandro Sette, PhD (La Jolla Institute), Ezra Cohen, MD (Solid Tumor Therapeutics), Bjoern Peters, PhD (Structural and Functional Genomics), and Stephen Schoenberger, PhD (Solid Tumor Therapeutics)

European Urology

Loren Mell, MD (Solid Tumor Therapeutics)

PI:  Lyudmila Bazhenova, MD

NCT: NCT04449874

PI: Ramez Eskander, MD

NCT: NCT05128825

PI: Shumei Kato, MD

NCT: Not in CT.gov

PI: Sandip Patel, MD

NCT: NCT06051695

Join COE next Thursday, April 18 at 12:00 p.m. for the first session of the Cervical Cancer Quality Improvement Learning Collaborative, which will present the promise of HPV self-testing, spotlight access to care, and highlight current resources and future visions for cervical cancer screening and prevention. This event is open to clinicians, public health practitioners, quality improvement staff, health educators, and community members interested in learning more.

COE was proud to support this symposium produced by consortium partner SDSU's School of Public Health, titled "Cancer Health Disparities: Challenges and Opportunities From Bench to Community" on the evening of April 11, 2024. Audience members (1) heard the latest research updates in the field of cancer health disparities from Moores Associate Director of Equity, Diversity and Inclusion, Dr. Melody Schiaffino; Co-Director, Center for Health Equity Education and Research, Dr. Mateo Banegas; and Medical Oncologist and Assistant Professor of Medicine, Dr. Angelique Richardson and (2) discussed how public health practitioners, researchers and community members can bridge the gaps and pave the way for equitable health outcomes.

Department of Research Administration

3855 Health Sciences Drive, La Jolla, CA 92037

moorescancercenter.ucsd.edu

Unsubscribe | Privacy Policy | Submit Feedback